Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Niagen Bioscience (NAGE) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for Niagen Bioscience (NAGE) over the last 17 years, with Q3 2025 value amounting to 12.46%.

  • Niagen Bioscience's EBITDA Margin rose 62000.0% to 12.46% in Q3 2025 from the same period last year, while for Sep 2025 it was 15.48%, marking a year-over-year increase of 149900.0%. This contributed to the annual value of 7.76% for FY2024, which is 144600.0% up from last year.
  • Niagen Bioscience's EBITDA Margin amounted to 12.46% in Q3 2025, which was up 62000.0% from 10.24% recorded in Q2 2025.
  • In the past 5 years, Niagen Bioscience's EBITDA Margin registered a high of 24.42% during Q4 2024, and its lowest value of 51.08% during Q3 2021.
  • Its 5-year average for EBITDA Margin is 12.24%, with a median of 6.88% in 2022.
  • In the last 5 years, Niagen Bioscience's EBITDA Margin plummeted by -214900bps in 2021 and then surged by 360700bps in 2023.
  • Quarter analysis of 5 years shows Niagen Bioscience's EBITDA Margin stood at 29.93% in 2021, then skyrocketed by 77bps to 6.88% in 2022, then soared by 88bps to 0.79% in 2023, then soared by 3180bps to 24.42% in 2024, then tumbled by -49bps to 12.46% in 2025.
  • Its EBITDA Margin stands at 12.46% for Q3 2025, versus 10.24% for Q2 2025 and 15.66% for Q1 2025.